Ex-Transkaryotic CEO settles SEC charges for $1.1M

Richard Selden, the former CEO of Transkaryotic Therapies, has agreed to pay more than $1.1 million to settle claims he misled investors and improperly pumped up the value of the company's stock by inflating the potential of Replagal. The SEC had accused Selden of covering up the fact that the drug had failed a trial for Fabry's disease and knew regulators were likely to reject an application for the drug. Transkaryotic didn't tell investors that it knew it would have to undertake more clinical trial work before Selden sold 90,000 shares of company stock. The SEC says Selden gained $1.6 million in profits. He was fired in early 2003 and Transkaryotic was sold to Shire in 2005 for $1.6 billion.

- read the story from the Boston Globe

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."